Hyderabad, India and Princeton, NJ, USA. February 2, 2018: Dr. Reddy’s Laboratories Ltd has launched Tetrabenazine tablets, a therapeutic equivalent generic version of Xenazine (tetrabenazine) in the US market with approval from the US Food and Drug Administration (USFDA). The drug is indicated for the treatment of chorea (uncontrolled muscle movements).
The Xenazine brand and generic had US sales of approximately $322 million for the most recent 12 months ending in November 2017, according to IMS Health. The Hyderabad-based Dr. Reddy’s Tetrabenazine tablets are available in strengths of 12.5 mg and 25 mg, each strength is available in a bottle count size of 112.
Xenazine is a registered trademark of Valeant Pharmaceuticals Luxembourg S.A.R.L. Dr. Reddy’s script is almost flat on the Bombay Stock Exchange on Friday and is trading at Rs 2,154.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics, and Proprietary Products – Dr. Reddy’s offer a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to:www.drreddys.com